AbbVie Acquires Allergan for US$63 B to Ease Humira Fears
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 7 (Table of Contents)
Published: 2 Jul-2019
DOI: 10.3833/pdr.v2019.i7.2438 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In the second largest M&A deal of 2019 so far, AbbVie has agreed to acquire Allergan for approximately US$63 B in an effort to ease investor concerns regarding AbbVie’s over-reliance on Humira® (adalimumab)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS